Cytokinetics lifts curtain on Phase 3 aficamten data, commercial launch prep underway - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Cytokinetics detailed results on Monday from a late-stage trial of aficamten for a rare heart disease, and the company is already hiring medical affairs and payer interaction staff as it prepares for a potential launch. “The study hit on not only its primary …